News & Updates

Application of delgocitinib cream results in significant improvements in itch, pain, and quality of life (QoL) at week 16 in adults with moderate to severe chronic hand eczema (CHE), as shown in the pooled analysis of the phase III DELTA-1 and -2 trials.

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.

Findings from the phase III ROCKET-SHUTTLE trial support the treatment potential of rocatinlimab for atopic dermatitis (AD).

Treatment with bimekizumab for 4 years results in satisfactory levels of clinical and health-related quality of life responses, reports a study. The majority of patients with moderate-to-severe plaque psoriasis achieve near-complete skin clearance, while nearly two-thirds have complete skin clearance.